DJIA 18,053.71 23.50 0.13%
NASDAQ 4,806.86 33.39 0.70%
S&P 500 2,088.77 6.89 0.33%
market minute promo

Gilead Sciences (NASDAQ: GILD)



company name or ticker
Company Photos
(Click to zoom)

AbbVie's All-Oral, Interferon-Free HCV Treatment Approved - Analyst Blog

Gilead/Ono Pharmaceutical Ink Deal for Blood Cancer Drug - Analyst Blog

Jim Cramer's 'Mad Money' Recap: Biotech Sector Havoc Can't Be Ignored

Commentary On Gilead Sciences' Recent Plunge

Why Gilead Sciences Shares Tumbled Today

Gilead Sciences shares fell sharply on concerns that competition from AbbVie's hepatitis C drug puts its market share at risk.

Bulls Make New Record High Despite Biotech Blues

Today's financial recap and tomorrow's financial outlook.

Week Ahead Market Report: December 22, 2014

Express Scripts Knocks Gilead's Hepatitis C Drug in Favor of AbbVie

Why I Am Not Selling Gilead

Monday's ETF Movers: EEM, BBH

See More Articles...